Vantage logo

The Cymabay recovery continues

Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.

Vantage logo

The dream is over for Intercept

The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.

Vantage logo

Novo’s Nash play takes shape

As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.